Daratumumab (Dara), a human IgG-k monoclonal antibody that targets CD38, is a highly effective antiplasma cell therapy, and it was recently added to the therapeutic MM armamentarium with an unprecedented depth of responses [12,13,14,15]. This evidence concerns the gene CD38 and Miyoshi myopathy.